Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.

Adrenal Cortex Neoplasms / genetics Adrenocortical Carcinoma / genetics Adult Biomarkers, Tumor / biosynthesis Female Humans Male Middle Aged Real-Time Polymerase Chain Reaction / methods Receptor, Fibroblast Growth Factor, Type 1 / biosynthesis Receptor, Fibroblast Growth Factor, Type 4 / biosynthesis Survival Rate / trends
FGF-pathway FGFR RNA Expression RNAScope adrenocortical tumors normal adrenal glands patient survival unsupervised clustering

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 14 10 2021
accepted: 23 11 2021
entrez: 27 12 2021
pubmed: 28 12 2021
medline: 19 2 2022
Statut: epublish

Résumé

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and treatment of advanced disease is challenging. Clinical trials with multi-tyrosine kinase inhibitors in the past have yielded disappointing results. Here, we investigated fibroblast growth factor (FGF) receptors and their pathways in adrenocortical tumors as potential treatment targets. We performed real-time RT-PCR of 93 FGF pathway related genes in a cohort of 39 fresh frozen benign and malignant adrenocortical, 9 non-adrenal tissues and 4 cell lines. The expression of FGF receptors was validated in 166 formalin-fixed paraffin embedded (FFPE) tissues using RNA

Identifiants

DOI: 10.3389/fendo.2021.795116 PMID: 34956100 PMC: PMC8699171
pubmed: 34956100
doi: 10.3389/fendo.2021.795116
pmc: PMC8699171
doi:

Substances chimiques

Biomarkers, Tumor 0
FGFR1 protein, human EC 2.7.10.1
FGFR4 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 4 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

795116

Informations de copyright

Copyright © 2021 Sbiera, Kircher, Altieri, Lenz, Hantel, Fassnacht, Sbiera and Kroiss.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancers (Basel). 2021 Apr 06;13(7):
pubmed: 33917436
N Engl J Med. 2007 Jun 7;356(23):2372-80
pubmed: 17554118
Biol Pharm Bull. 2007 Oct;30(10):1819-25
pubmed: 17917244
Oncotarget. 2017 Apr 28;8(34):56569-56581
pubmed: 28915613
Endocrinology. 2014 Sep;155(9):3550-60
pubmed: 24956203
Endocr Relat Cancer. 2009 Jun;16(2):573-83
pubmed: 19218281
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Int J Cancer. 2019 Sep 1;145(5):1346-1357
pubmed: 30807645
Eur J Endocrinol. 2012 Mar;166(3):451-8
pubmed: 22189997
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 31900481
Cancer Cell. 2016 May 9;29(5):723-736
pubmed: 27165744
Annu Rev Biochem. 1989;58:575-606
pubmed: 2549857
Lancet Oncol. 2015 Apr;16(4):426-35
pubmed: 25795408
J Biochem. 2011 Feb;149(2):121-30
pubmed: 20940169
Mol Cell Endocrinol. 2013 May 22;371(1-2):182-8
pubmed: 23376610
Mol Cancer Res. 2010 Nov;8(11):1439-52
pubmed: 21047773
BMC Res Notes. 2020 Jun 10;13(1):282
pubmed: 32522271
Sci Rep. 2015 Mar 11;5:8997
pubmed: 25757764
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
Br J Cancer. 2021 Mar;124(5):880-892
pubmed: 33268819
J Geriatr Oncol. 2019 Sep;10(5):749-756
pubmed: 30952517
Cancer Sci. 2009 May;100(5):844-51
pubmed: 19220297
Eur J Endocrinol. 2009 Jul;161(1):141-52
pubmed: 19411298
Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101434
pubmed: 32622829
Endocrinology. 1975 Jul;97(1):102-7
pubmed: 166822
Clin Cancer Res. 2021 Sep 30;:
pubmed: 34593528
Endocrinology. 2013 May;154(5):1754-67
pubmed: 23471215
Mol Cell Endocrinol. 2004 Jul 30;222(1-2):9-20
pubmed: 15249121
Cancers (Basel). 2019 Aug 12;11(8):
pubmed: 31408968
Endocr Relat Cancer. 2012 May 03;19(3):L11-3
pubmed: 22241720
Physiol Genomics. 2004 Sep 16;19(1):106-16
pubmed: 15375197
J Clin Oncol. 2010 Aug 10;28(23):e401-2; author reply e403
pubmed: 20567001
Mech Dev. 2000 Oct;97(1-2):201-4
pubmed: 11025226
Mol Cell Endocrinol. 2015 Sep 15;413:168-77
pubmed: 26141512
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Dev Biol. 2005 Nov 15;287(2):390-402
pubmed: 16216232
Endocr Relat Cancer. 2018 Apr;25(4):437-451
pubmed: 29371329
Nat Commun. 2020 Apr 3;11(1):1680
pubmed: 32245949
Cancer Res. 1995 Dec 15;55(24):6215-21
pubmed: 8521416
Prog Growth Factor Res. 1991;3(2):103-13
pubmed: 1663405
Cancer Manag Res. 2019 May 01;11:3847-3860
pubmed: 31118801
Endocrine. 2011 Dec;40(3):445-51
pubmed: 21706269
J Cell Biol. 2001 May 14;153(4):811-22
pubmed: 11352941
Endocrinology. 2000 Sep;141(9):3127-36
pubmed: 10965883
J Clin Endocrinol Metab. 2012 Oct;97(10):3495-503
pubmed: 22837187
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
Curr Cancer Drug Targets. 2009 Aug;9(5):639-51
pubmed: 19508171
Mol Oncol. 2018 Jun;12(7):993-1003
pubmed: 29573334
Front Endocrinol (Lausanne). 2021 Aug 12;12:712107
pubmed: 34475850
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Endocrinology. 1977 Apr;100(4):1080-9
pubmed: 189990
Eur Respir J. 2019 Feb 28;53(2):
pubmed: 30578395
Oncotarget. 2016 Nov 29;7(48):79292-79304
pubmed: 27764813
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Nephrol Dial Transplant. 2019 Jan 1;34(1):15-21
pubmed: 29800324
Minerva Endocrinol. 2019 Mar;44(1):43-57
pubmed: 29963827
J Clin Endocrinol Metab. 2015 Mar;100(3):841-9
pubmed: 25559399
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32737143
Front Endocrinol (Lausanne). 2011 Sep 09;2:27
pubmed: 22654799
Carcinogenesis. 2017 May 1;38(5):559-569
pubmed: 28383667
Clin Cancer Res. 2011 Oct 1;17(19):6130-9
pubmed: 21953501
J Endocrinol. 2007 Feb;192(2):459-65
pubmed: 17283246
Onco Targets Ther. 2019 Jan 18;12:635-645
pubmed: 30705592
J Clin Endocrinol Metab. 2013 Oct;98(10):4080-8
pubmed: 23979958
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107

Auteurs

Iuliu Sbiera (I)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Stefan Kircher (S)

Institute of Pathology, University of Würzburg, Würzburg, Germany.

Barbara Altieri (B)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Kerstin Lenz (K)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Constanze Hantel (C)

Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zürich (USZ) and University of Zürich (UZH), Zürich, Switzerland.
Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.

Martin Fassnacht (M)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Clinical Chemistry and Laboratory Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

Silviu Sbiera (S)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.

Matthias Kroiss (M)

Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
Department of Internal Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs de la surrénale › Tumeurs corticosurrénaliennes › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs de la surrénale › Tumeurs corticosurrénaliennes › Carcinome corticosurrénalien › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › Réaction de polymérisation en chaine en temps réel › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteur facteur croissance fibroblaste › Récepteur FGFR1 › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteur facteur croissance fibroblaste › Récepteur FGFR4 › Role of FGF Receptors and Their Pathways in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Role of FGF Receptors and Their Pathways in...